Bristol’s DTC Moratorium Will Affect Muraglitazar, Abatacept Launches

Muraglitazar and abatacept are likely to be the first Bristol-Myers Squibb products significantly affected by the company's recent moratorium on direct-to-consumer advertising during a drug's first 12 months on the market